FDA clears Claret Medical’s Sentinel TAVR stroke protection device for U.S. market

FDA gives nod to Claret Medical's Sentinel TAVR stroke prevention device.

The FDA has cleared the use of Claret Medical’s Sentinel cerebral protection system in the U.S., making the device the first and only of its kind on the market that reduces the risk of stroke by capturing and removing debris that can break free during transcatheter aortic valve replacement (TAVR) and cause a stroke, the company said.

The regulatory agency cleared the device under de novo classification, which allows for a speedier approval process for low- to moderate-risk devices. The company said it expects to make Sentinel available in certain high-volume TAVR centers immediately and is working to make the device eligible for CMS reimbursement. 

Data from the pivotal Sentinel trial showed the device reduced strokes by 63% in the first 72 hours after TAVR and maintained a substantial difference at 90 days. Additional studies indicated the device removed visible debris headed towards the brain in 99% of TAVR cases, regardless of the type of replacement valve used and with no added risk.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We believe that Sentinel will create a paradigm shift in how TAVR patients are treated in the U.S.,” Azin Parhizgar, Claret Medical’s president and CEO, said in a statement. “The science behind the device has set a high bar for other embolic protection devices to meet and its safety record is indisputable.”

The Sentinel system was evaluated in more than 1,000 patients in multiple studies, including three randomized controlled trials, making it one of the most studied TAVR devices, the company said. To date, more than 3,500 patients globally have been protected with the device, and Sentinel is the only cerebral protection system commercially available in Europe, selected Asian countries and the U.S.

Other big players in the TAVR field are Boston Scientific, Medtronic and Edwards Lifesciences..

Read more on

Suggested Articles

Amgen has tapped Adaptive Biotechnologies to deliver next-generation sequencing assays as it moves its blood cancer drugs toward approval.

Bayer led One Drop’s $40 million series B round and licensed its technology for its “bio-digital efforts” in areas such as cancer and heart disease.

Abbott has received European approvals for two devices designed for children and infants with life-threatening heart defects.